Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat Media A Fresh IPO That Long-Term Investors Shouldn't IgnoreSubmitted by Jordan Chussler. First Published: 1/14/2026. 
Summary - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Almost every week companies go public, and a handful often offer meaningful short-term upside potential. Of course, IPOs carry substantial downside risk. But even conservative investors should not automatically dismiss recent market debuts—some newly public companies can deserve a place in buy-and-hold portfolios. Wall Street: "[This Tiny $4 Trillion Market] is a Generational Buying Opportunity." A Revolutionary New Rule is Racing Through Washington. Prepare Here Now. For one biotechnology company in the healthcare sector that just went public, that may be precisely the case. Last Year’s IPO Success Stories Last year provides a useful reminder that not all IPOs are pure speculation—some have rewarded patient investors. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since its debut. Short-term speculators captured an early peak—roughly a 359% gain within 30 days of listing—but longer-term holders are still enjoying strong returns. Others, such as Medline (NASDAQ: MDLN), challenge the notion that IPOs are only for high-risk startups. The medical products and services provider, which publicly debuted in December 2025, was founded in 1966 and already has a market cap above $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—famous for its bacon products—waited 89 years before its IPO. Since going public in January 2025, the stock is up nearly 5% and has rewarded shareholders with a dividend that currently yields 4.44% (about $1 per share annually), making it attractive to income investors. Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals that began trading on Jan. 9, hopes to deliver similar outcomes in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology focuses on radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for diagnostics and the treatment of conditions such as cancer, heart disease and neurological disorders. Radiopharmaceuticals pair radioactive isotopes with a targeting component that seeks out specific cells (for example, cancer cells) to deliver localized radiation doses, minimizing damage to healthy tissue compared with some conventional treatments. Industry consultant Grand View Research estimates the global nuclear medicine market at nearly $18 billion in 2024, with a forecast to reach about $35 billion by 2030—a compound annual growth rate of roughly 10.16%. Grand View Research also notes that North America accounts for nearly 43% of the global nuclear medicine market, with the United States as the dominant regional player—important context for Boston-based Aktis Oncology. Aktis Oncology’s Clinical-Stage Profile Wall Street expects biotech IPOs to rebound in 2026 after funding changes the previous year slowed listings from the healthcare sector. Aktis Oncology, which debuted on the Nasdaq on Jan. 9, was the first biotech IPO of 2026 and achieved one of the larger recent raises for a biotech offering. The deal generated $318 million in IPO proceeds and the company now carries a market cap of about $3.34 billion. According to the company’s prospectus, the executive team includes drug development, approval and commercialization veterans who have helped bring 14 products that are currently FDA‑approved to market. At a technical level, Aktis develops targeted alpha radiopharmaceuticals, a class of precision oncology drugs that use proprietary targeting technology to attack solid tumors while sparing healthy tissue. Aktis Oncology’s Eli Lilly Connection Aktis is a clinical-stage, pre-revenue company, but that did not deter investors. Notably, Eli Lilly (NYSE: LLY) anchored the IPO. According to Reuters, Eli Lilly purchased $100 million of AKTS shares as part of the offering. That move builds on a 2024 partnership between the companies to develop tumor‑targeting radiopharmaceuticals, under which Eli Lilly committed $60 million in cash and an equity investment, with potential milestone payments that could exceed $1 billion. The significance of Lilly’s backing is substantial. At about $1.01 trillion, Eli Lilly ranks among the largest pharma companies by market cap; the company’s net income rose nearly 109% year‑over‑year from 2023 to 2024. That momentum may continue when Eli Lilly reports Q4 and full‑year 2025 financials on Feb. 5. Between its equity stake and the $100 million in AKTS shares purchased in the IPO, the maker of Zepbound has a meaningful financial interest in Aktis Oncology’s future success.
| 
